drugset / Trial / NCT03216473

Clinical Study to Evaluate the Efficacy and Safety of Neuronox and Botox With Essential Blepharospasm

NCT03216473

Phase 3 Completed 140 enrolled Medy-Tox
RandomizedParallel-groupDouble-blindTreatment

Summary

This clinical study evaluates the efficacy and safety of Neuronox compared with Botox in adults with essential blepharospasm.

Timeline

Start
2016-05-25
Primary completion
2017-03-17
Completion
2017-07-04

Drugs

EvaluationDrugModalityDoseRoute
Comparator Botulinum toxin type A Protein / enzyme biologic 100 iu
Subject Neuronox Protein / enzyme biologic 100 iu